Access innovative fatty liver treatments while advancing medical research by participating in one of our clinical trials evaluating a potential new treatment option.
Those who qualify and choose to participate will be compensated!
This research study is for adults ages 18 to 75 who have a liver biopsy confirmation of fatty liver disease, known as Metabolic Dysfunction-Associated Steatohepatitis (MASH), consistent with stage F2 or F3 fibrosis. The study is evaluating an investigational medication GSK6519754 to find out if it can help reduce the fat, inflammation, and scarring tissue in the liver. Additional aims are to assess how safe the medication is and how it is processed in the body compared to a placebo.
This study is randomized, double-blind, and placebo-controlled. If you qualify and decide to participate, you will have a 2 in 3 chance of receiving GSK6519754 and a 1 in 3 chance of receiving a placebo, which looks like the study drug but contains no active ingredient. These methods help to ensure the results are accurate and unbiased.
The study will include a screening period, a treatment period, and a follow-up period over about 4 years and 4 months, with 54 in-clinic visits required. If you qualify and participate, you may be compensated for your study-related time. Throughout the study, your health and progress will be carefully monitored by a team of board-certified physicians. By participating, you may help advance research that could bring new options to people living with MASH.
Those who qualify and choose to participate could receive:
A fibroscan a no cost , a non-invasive ultrasound test that measures the fattiness of the liver
Access to the investigational treatment at no cost
Access to our top-tier team of board-certified physicians at no cost
Compensation for
study related time
and travel
A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations.
Each study has its own set of inclusion and exclusion criteria that a participant must meet before they are allowed to participate in a study. Patients from all backgrounds and walks of life are encouraged to participate.
Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason.
A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo.
If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes.
All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be approved by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.